Literature DB >> 11571769

Frequency of behavioral symptoms characterizes agitation in Alzheimer's disease.

R E Tractenberg1, A Gamst, M F Weiner, E Koss, R G Thomas, L Teri, L Thal.   

Abstract

This study describes two well-characterized groups of Alzheimer's disease (AD) patients with similar levels of cognitive functioning, but with different overall behavioral disturbance levels. We sought to determine the nature of this difference-whether AD patients with higher levels of behavioral disturbance (n = 148) differ from less disturbed AD patients (n = 235) in terms of (a) the range of symptoms exhibited, (b) the frequency of occurrence of these symptoms, or (c) both of these. We defined and operationalized 'diversity of behaviors' and 'frequency' with respect to the item-level responses on the Cohen-Mansfield agitation inventory (CMAI). We found that, in these two samples of AD patients, differences occurred in the frequency of 10 out of 21 behaviors, rather than in a variety of endorsed behaviors. These 10 behaviors, observed at different frequencies in both groups, may be useful for monitoring change in studies of drugs or behavioral interventions for behavioral disturbance in persons with AD. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11571769      PMCID: PMC4373072          DOI: 10.1002/gps.441

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  17 in total

1.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

Authors:  I R Katz; D V Jeste; J E Mintzer; C Clyde; J Napolitano; M Brecher
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.

Authors:  D P Devanand; K Marder; K S Michaels; H A Sackeim; K Bell; M A Sullivan; T B Cooper; G H Pelton; R Mayeux
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

4.  A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.

Authors:  S H Ferris; J A Mackell; R Mohs; L S Schneider; D Galasko; P J Whitehouse; F A Schmitt; M Sano; R G Thomas; C Ernesto; M Grundman; K Schafer; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

Review 5.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

6.  Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study.

Authors:  R G Logsdon; L Teri; M F Weiner; L E Gibbons; M Raskind; E Peskind; M Grundman; E Koss; R G Thomas; L J Thal
Journal:  J Am Geriatr Soc       Date:  1999-11       Impact factor: 5.562

Review 7.  Assessment of behavioral symptoms in Alzheimer disease.

Authors:  M B Patterson; J P Bolger
Journal:  Alzheimer Dis Assoc Disord       Date:  1994       Impact factor: 2.703

8.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.

Authors:  P N Tariot; R Erb; C A Podgorski; C Cox; S Patel; L Jakimovich; C Irvine
Journal:  Am J Psychiatry       Date:  1998-01       Impact factor: 18.112

Review 9.  Measures of psychiatric symptoms in Alzheimer patients: a review.

Authors:  M F Weiner; E Koss; K V Wild; D G Folks; P Tariot; H Luszczynska; P Whitehouse
Journal:  Alzheimer Dis Assoc Disord       Date:  1996       Impact factor: 2.703

10.  The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

Authors:  P N Tariot; J L Mack; M B Patterson; S D Edland; M F Weiner; G Fillenbaum; L Blazina; L Teri; E Rubin; J A Mortimer
Journal:  Am J Psychiatry       Date:  1995-09       Impact factor: 18.112

View more
  3 in total

1.  Characterizing sleep problems in persons with Alzheimer's disease and normal elderly.

Authors:  Rochelle E Tractenberg; Clifford M Singer; Jeffrey A Kaye
Journal:  J Sleep Res       Date:  2006-03       Impact factor: 3.981

2.  Restless legs syndrome risk factors, behaviors, and diagnoses in persons with early to moderate dementia and sleep disturbance.

Authors:  Kathy Richards; Valorie M Shue; Cornelia K Beck; Corinne W Lambert; Donald L Bliwise
Journal:  Behav Sleep Med       Date:  2010       Impact factor: 2.964

3.  Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease.

Authors:  Rochelle E Tractenberg; Myron F Weiner; Marian B Patterson; Linda Teri; Leon J Thal
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-06       Impact factor: 2.680

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.